Chief Executive Officer Kumar Neil sold $4,983,111 worth of shares (80,000 units at $62.29) (SEC Form 4)
$BBIO
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
|
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | ||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
|
3. Date of Earliest Transaction
(Month/Day/Year) 11/06/2025 | ||||||||||||||||||||||||||
|
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Common Stock | 11/06/2025 | S(1) | 12,576 | D | $62.9108(2) | 4,625,871 | I | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3) | ||
| Common Stock | 11/06/2025 | S(1) | 7,324 | D | $63.5467(4) | 4,618,547 | I | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3) | ||
| Common Stock | 11/06/2025 | S(1) | 100 | D | $64.39 | 4,618,447 | I | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3) | ||
| Common Stock | 11/07/2025 | S(1) | 12,492 | D | $61.1401(5) | 4,605,955 | I | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3) | ||
| Common Stock | 11/07/2025 | S(1) | 7,308 | D | $61.8714(6) | 4,598,647 | I | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3) | ||
| Common Stock | 11/07/2025 | S(1) | 200 | D | $62.805(7) | 4,598,447 | I | By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3) | ||
| Common Stock | 11/06/2025 | S(1) | 12,529 | D | $62.9088(2) | 823,157 | I | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3) | ||
| Common Stock | 11/06/2025 | S(1) | 7,371 | D | $63.5561(4) | 815,786 | I | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3) | ||
| Common Stock | 11/06/2025 | S(1) | 100 | D | $64.39 | 815,686 | I | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3) | ||
| Common Stock | 11/07/2025 | S(1) | 12,234 | D | $61.1298(8) | 803,452 | I | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3) | ||
| Common Stock | 11/07/2025 | S(1) | 7,546 | D | $61.8657(9) | 795,906 | I | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3) | ||
| Common Stock | 11/07/2025 | S(1) | 220 | D | $62.7936(10) | 795,686 | I | By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3) | ||
| Common Stock | 223,090 | D | ||||||||
|
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Explanation of Responses: |
| 1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. |
| 2. Represents the weighted average sale price of the shares sold from $62.245 to $63.24 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| 3. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. |
| 4. Represents the weighted average sale price of the shares sold from $63.25 to $64.17 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| 5. Represents the weighted average sale price of the shares sold from $60.59 to $61.58 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| 6. Represents the weighted average sale price of the shares sold from $61.59 to $62.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| 7. Represents the weighted average sale price of the shares sold from $62.78 to $62.83 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| 8. Represents the weighted average sale price of the shares sold from $60.57 to $61.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| 9. Represents the weighted average sale price of the shares sold from $61.58 to $62.37 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| 10. Represents the weighted average sale price of the shares sold from $62.68 to $62.83 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. |
| Remarks: |
| /s/ Will Solis, Attorney-in-Fact | 11/10/2025 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||